Literature DB >> 21969494

Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma.

Sebastiano Buti1, Maddalena Donini, Pietro Sergio, Lorella Garagnani, Laura Schirosi, Rodolfo Passalacqua, Giulio Rossi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21969494     DOI： 10.1200/JCO.2011.36.6427

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  10 in total

1.  Effects of endoplasmic reticulum stressors on maturation and signaling of hemizygous and heterozygous wild-type and mutant forms of KIT.

Authors:  Sabrina Brahimi-Adouane; Jean-Baptiste Bachet; Séverine Tabone-Eglinger; Frédéric Subra; Claude Capron; Jean-Yves Blay; Jean-François Emile
Journal:  Mol Oncol       Date:  2012-10-30       Impact factor: 6.603

2.  Thymic neoplasm: a rare disease with a complex clinical presentation.

Authors:  Omar M Rashid; Anthony D Cassano; Kazuaki Takabe
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

3.  c-kit mutation-positive advanced thymic carcinoma successfully treated as a mediastinal gastrointestinal stromal tumor: A case report.

Authors:  Fumihiko Hirai; Makoto Edagawa; Shinichiro Shimamatsu; Ryo Toyozawa; Gouji Toyokawa; Kaname Nosaki; Masafumi Yamaguchi; Takashi Seto; Mitsuhiro Twakenoyama; Yukito Ichinose
Journal:  Mol Clin Oncol       Date:  2016-01-28

4.  Thymic cancer in lynch syndrome: an unusual association.

Authors:  Deepali Pandey; David Scott Shepro
Journal:  BMJ Case Rep       Date:  2020-04-08

5.  Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E.

Authors:  Chiara Catania; Fabio Conforti; Gianluca Spitaleri; Massimo Barberis; Lorenzo Preda; Cristina Noberasco; Chiara Lazzari; Francesca Toffalorio; Filippo de Marinis; Michela Manzotti; Tommaso Martino De Pas
Journal:  Onco Targets Ther       Date:  2014-05-08       Impact factor: 4.147

Review 6.  Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells.

Authors:  Maryam Abbaspour Babaei; Behnam Kamalidehghan; Mohammad Saleem; Hasniza Zaman Huri; Fatemeh Ahmadipour
Journal:  Drug Des Devel Ther       Date:  2016-08-01       Impact factor: 4.162

7.  Targeted Next-Generation Sequencing of Thymic Epithelial Tumours Revealed Pathogenic Variants in KIT, ERBB2, KRAS, and TP53 in 30% of Thymic Carcinomas.

Authors:  Adam Szpechcinski; Malgorzata Szolkowska; Sebastian Winiarski; Urszula Lechowicz; Piotr Wisniewski; Magdalena Knetki-Wroblewska
Journal:  Cancers (Basel)       Date:  2022-07-12       Impact factor: 6.575

8.  Phosphoproteomic Analysis Identifies TYRO3 as a Mediator of Sunitinib Resistance in Metastatic Thymomas.

Authors:  Stefan Küffer; Jessica Grabowski; Satoru Okada; Nikolai Sojka; Stefan Welter; Alexander von Hammerstein-Equord; Marc Hinterthaner; Lucia Cordes; Xenia von Hahn; Denise Müller; Christian Sauer; Hanibal Bohnenberger; Alexander Marx; Philipp Ströbel
Journal:  Cancers (Basel)       Date:  2022-09-29       Impact factor: 6.575

9.  Expression and significance of c-kit and epithelial-mesenchymal transition (EMT) molecules in thymic epithelial tumors (TETs).

Authors:  Zhigang Wu; Songtao Xue; Bin Zheng; Rongjin Ye; Guobing Xu; Shuliang Zhang; Taidui Zeng; Wei Zheng; Chun Chen
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

10.  KRAS, EGFR, PDGFR-α, KIT and COX-2 status in carcinoma showing thymus-like elements (CASTLE).

Authors:  Lothar Veits; Rupert Schupfner; Petra Hufnagel; Roland Penzel; Jens Freitag; Philipp Ströbel; Michael A Kern; Sören Schröder; Nikolaus Neuhold; Kurt W Schmid; Peter Schirmacher; Arndt Hartmann; Ralf J Rieker
Journal:  Diagn Pathol       Date:  2014-06-16       Impact factor: 2.644
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.